Daratumumab (Dara), a monoclonal antibody directed against CD38, is highly effective in treating myeloma and improves response rates and progression free survival (PFS) when added to PI or IMiD. Ixazomib, lenalidomide and dexamethasone (IRd) is an effective, all oral, induction regimen that has ...
2. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. Published online December 12, 2023. doi:10.1056/NEJMoa2312054 (声明:文中图片来源于网络共享,如涉及侵权请联系作者删除处理) ...
2. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. Published online December 12, 2023. doi:10.1056/NEJMoa2312054
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. PMID: 34192431 Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. PMID: 27557302 Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. PMID: 31141632
在不符合自体干细胞移植的新诊断多发性骨髓瘤患者中, daratumumab、来那度胺联合地塞米松治疗可显著降低患者疾病进展风险。 原始出处: Thierry Facon et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med, May 30, 2019 医研荟MedHub©...
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. Daratumumab, a human IgG魏 monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as mo... Antonio,Palumbo,Asher,... - 《New England Journal of Medicine》 被引量: ...
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaAuthor(s): Pieter Sonneveld 1 , Meletios A. Dimopoulos 1 , Mario Boccadoro 1 , Hang Quach 1 , P. Joy Ho 1 , Meral Beksac 1 , Cyrille Hulin 1 , Elisabetta Antonioli 1 , Xavier Leleu 1 , Silvia Mangiacavalli ...
Subcutaneous Daratumumab Plus VRd Receives FDA Approval for Multiple Myeloma Daratumumab and hyaluronidase-fihj (Darzalex Faspro) was approved by the FDA in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Darzalex Faspro-VRd) for induction and consolidation in pat...
89%的患者对来那度胺耐药,71%的患者对硼替佐米(bortezomib)耐药,64%的患者对硼替佐米和来那度胺耐药。 参考文献: [1]FDA ApprovesDaratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed orRefractory Multiple Myeloma [2]Genmab官网...